Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study
Summary Background We conducted a prospective multicenter case–control study to confirm the clinical efficacy and safety of Waon therapy on chronic heart failure (CHF). Methods Patients ( n = 188) with CHF were treated with standard therapy for at least 1 week, and then were randomized to Waon thera...
Gespeichert in:
| Veröffentlicht in: | Journal of cardiology 2008-10, Vol.52 (2), p.79-85 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 85 |
|---|---|
| container_issue | 2 |
| container_start_page | 79 |
| container_title | Journal of cardiology |
| container_volume | 52 |
| creator | Miyata, Masaaki, MD, FJCC Kihara, Takashi, MD Kubozono, Takuro, MD Ikeda, Yoshiyuki, MD Shinsato, Takuro, MD Izumi, Toru, MD, FJCC Matsuzaki, Masunori, MD, FJCC Yamaguchi, Tetsu, MD, FJCC Kasanuki, Hiroshi, MD, FJCC Daida, Hiroyuki, MD, FJCC Nagayama, Masatoshi, MD Nishigami, Kazuhiro, MD Hirata, Kumiko, MD Kihara, Koichi, MD Tei, Chuwa, MD, FJCC |
| description | Summary Background We conducted a prospective multicenter case–control study to confirm the clinical efficacy and safety of Waon therapy on chronic heart failure (CHF). Methods Patients ( n = 188) with CHF were treated with standard therapy for at least 1 week, and then were randomized to Waon therapy ( n = 112) or a control group ( n = 76). All patients continued conventional treatment for an additional 2 weeks. The Waon therapy group was treated daily with a far infrared-ray dry sauna at 60 °C for 15 min and then kept on bed rest with a blanket for 30 min for 2 weeks. Chest radiography, echocardiography, and plasma levels of brain natriuretic peptide (BNP) were measured before and 2 weeks after treatment. Results NYHA functional class significantly decreased after 2 weeks of treatment in both groups. Chest radiography also showed a significant decrease of the cardiothoracic ratio in both groups (Waon therapy: 57.2 ± 8.0% to 55.2 ± 8.0%, p < 0.0001; control: 57.0 ± 7.7% to 56.0 ± 7.1%, p < 0.05). Echocardiography demonstrated that left ventricular diastolic dimension (LVDd), left atrial dimension (LAD), and ejection fraction (EF) significantly improved in the Waon therapy group (LVDd: 60.6 ± 7.6 to 59.1 ± 8.4 mm, p < 0.0001; LAD: 45.4 ± 9.3 mm to 44.1 ± 9.4 mm, p < 0.05; EF: 31.6 ± 10.4% to 34.6 ± 10.6%, p < 0.0001), but not in the control group (LVDd: 58.4 ± 10.3 mm to 57.9 ± 10.4 mm; LAD: 46.3 ± 9.7 mm to 46.2 ± 10.1 mm; EF: 36.6 ± 14.1% to 37.3 ± 14.0%). The plasma concentration of BNP significantly decreased with Waon therapy, but not in the control group (Waon: 542 ± 508 pg/ml to 394 ± 410 pg/ml, p < 0.001; control: 440 ± 377 pg/ml to 358 ± 382 pg/ml). Conclusion Waon therapy is safe, improves clinical symptoms and cardiac function, and decreases cardiac size in CHF patients. Waon therapy is an innovative and promising therapy for patients with CHF. |
| doi_str_mv | 10.1016/j.jjcc.2008.07.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733744715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0914508708002001</els_id><sourcerecordid>733744715</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-3187f7c0251cce425ec015321e88108a04f4a70a39df0c2aba8ed81dcb4ad1543</originalsourceid><addsrcrecordid>eNp9kV2r1DAQhoMonj2rf8ALyZ1XrZM03aQigh6OH3BA8AMvQ3Y6YVO7bU3aI_vvTdkFwQuvEpJ5H2aeYeyZgFKA2L3syq5DLCWAKUGXAM0DthFG7wqlK_OQbaARqqjB6Ct2nVIHsIPG7B6zK2EaKSsjNmx5RwP5gMH1nLwnnBMfPf_hxoHPB4puOvF8ndwcaMh_v8N84HiI4xCQH8jFmXsX-iXSK_6F0tKf845PcUxTxoV74sf8HDDnKfI0L-3pCXvkXZ_o6eXcsu_vb7_dfCzuPn_4dPP2rsAa9FxUeRivEWQtEEnJmhBEXUlBxggwDpRXToOrmtYDSrd3hlojWtwr14paVVv24szN3fxaKM32GBJS37uBxiVZXVVaKZ2ZWybPlZj7TpG8nWI4uniyAuxq23Z2tW1X2xa0zbZz6PkFv-yP1P6NXPTmgtfnAspD3geKNmH2iNSGmN3Ydgz_57_5J459yOJd_5NOlLpxiUPWZ4VN0oL9uu57XTcYgMwR1R8FFqdW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733744715</pqid></control><display><type>article</type><title>Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Miyata, Masaaki, MD, FJCC ; Kihara, Takashi, MD ; Kubozono, Takuro, MD ; Ikeda, Yoshiyuki, MD ; Shinsato, Takuro, MD ; Izumi, Toru, MD, FJCC ; Matsuzaki, Masunori, MD, FJCC ; Yamaguchi, Tetsu, MD, FJCC ; Kasanuki, Hiroshi, MD, FJCC ; Daida, Hiroyuki, MD, FJCC ; Nagayama, Masatoshi, MD ; Nishigami, Kazuhiro, MD ; Hirata, Kumiko, MD ; Kihara, Koichi, MD ; Tei, Chuwa, MD, FJCC</creator><creatorcontrib>Miyata, Masaaki, MD, FJCC ; Kihara, Takashi, MD ; Kubozono, Takuro, MD ; Ikeda, Yoshiyuki, MD ; Shinsato, Takuro, MD ; Izumi, Toru, MD, FJCC ; Matsuzaki, Masunori, MD, FJCC ; Yamaguchi, Tetsu, MD, FJCC ; Kasanuki, Hiroshi, MD, FJCC ; Daida, Hiroyuki, MD, FJCC ; Nagayama, Masatoshi, MD ; Nishigami, Kazuhiro, MD ; Hirata, Kumiko, MD ; Kihara, Koichi, MD ; Tei, Chuwa, MD, FJCC</creatorcontrib><description><![CDATA[Summary Background We conducted a prospective multicenter case–control study to confirm the clinical efficacy and safety of Waon therapy on chronic heart failure (CHF). Methods Patients ( n = 188) with CHF were treated with standard therapy for at least 1 week, and then were randomized to Waon therapy ( n = 112) or a control group ( n = 76). All patients continued conventional treatment for an additional 2 weeks. The Waon therapy group was treated daily with a far infrared-ray dry sauna at 60 °C for 15 min and then kept on bed rest with a blanket for 30 min for 2 weeks. Chest radiography, echocardiography, and plasma levels of brain natriuretic peptide (BNP) were measured before and 2 weeks after treatment. Results NYHA functional class significantly decreased after 2 weeks of treatment in both groups. Chest radiography also showed a significant decrease of the cardiothoracic ratio in both groups (Waon therapy: 57.2 ± 8.0% to 55.2 ± 8.0%, p < 0.0001; control: 57.0 ± 7.7% to 56.0 ± 7.1%, p < 0.05). Echocardiography demonstrated that left ventricular diastolic dimension (LVDd), left atrial dimension (LAD), and ejection fraction (EF) significantly improved in the Waon therapy group (LVDd: 60.6 ± 7.6 to 59.1 ± 8.4 mm, p < 0.0001; LAD: 45.4 ± 9.3 mm to 44.1 ± 9.4 mm, p < 0.05; EF: 31.6 ± 10.4% to 34.6 ± 10.6%, p < 0.0001), but not in the control group (LVDd: 58.4 ± 10.3 mm to 57.9 ± 10.4 mm; LAD: 46.3 ± 9.7 mm to 46.2 ± 10.1 mm; EF: 36.6 ± 14.1% to 37.3 ± 14.0%). The plasma concentration of BNP significantly decreased with Waon therapy, but not in the control group (Waon: 542 ± 508 pg/ml to 394 ± 410 pg/ml, p < 0.001; control: 440 ± 377 pg/ml to 358 ± 382 pg/ml). Conclusion Waon therapy is safe, improves clinical symptoms and cardiac function, and decreases cardiac size in CHF patients. Waon therapy is an innovative and promising therapy for patients with CHF.]]></description><identifier>ISSN: 0914-5087</identifier><identifier>EISSN: 1876-4738</identifier><identifier>DOI: 10.1016/j.jjcc.2008.07.009</identifier><identifier>PMID: 18922381</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Brain ; Cardiovascular ; Case-Control Studies ; Chronic Disease ; Echocardiography ; Female ; Heart failure ; Heart Failure - therapy ; Humans ; Hyperthermia, Induced - methods ; Male ; Middle Aged ; Natriuretic Peptide, Brain - blood ; Natriuretic peptides ; Non-pharmacological therapy ; Prospective Studies ; Radiography, Thoracic ; Treatment ; Waon therapy</subject><ispartof>Journal of cardiology, 2008-10, Vol.52 (2), p.79-85</ispartof><rights>Japanese College of Cardiology</rights><rights>2008 Japanese College of Cardiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-3187f7c0251cce425ec015321e88108a04f4a70a39df0c2aba8ed81dcb4ad1543</citedby><cites>FETCH-LOGICAL-c507t-3187f7c0251cce425ec015321e88108a04f4a70a39df0c2aba8ed81dcb4ad1543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0914508708002001$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18922381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyata, Masaaki, MD, FJCC</creatorcontrib><creatorcontrib>Kihara, Takashi, MD</creatorcontrib><creatorcontrib>Kubozono, Takuro, MD</creatorcontrib><creatorcontrib>Ikeda, Yoshiyuki, MD</creatorcontrib><creatorcontrib>Shinsato, Takuro, MD</creatorcontrib><creatorcontrib>Izumi, Toru, MD, FJCC</creatorcontrib><creatorcontrib>Matsuzaki, Masunori, MD, FJCC</creatorcontrib><creatorcontrib>Yamaguchi, Tetsu, MD, FJCC</creatorcontrib><creatorcontrib>Kasanuki, Hiroshi, MD, FJCC</creatorcontrib><creatorcontrib>Daida, Hiroyuki, MD, FJCC</creatorcontrib><creatorcontrib>Nagayama, Masatoshi, MD</creatorcontrib><creatorcontrib>Nishigami, Kazuhiro, MD</creatorcontrib><creatorcontrib>Hirata, Kumiko, MD</creatorcontrib><creatorcontrib>Kihara, Koichi, MD</creatorcontrib><creatorcontrib>Tei, Chuwa, MD, FJCC</creatorcontrib><title>Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study</title><title>Journal of cardiology</title><addtitle>J Cardiol</addtitle><description><![CDATA[Summary Background We conducted a prospective multicenter case–control study to confirm the clinical efficacy and safety of Waon therapy on chronic heart failure (CHF). Methods Patients ( n = 188) with CHF were treated with standard therapy for at least 1 week, and then were randomized to Waon therapy ( n = 112) or a control group ( n = 76). All patients continued conventional treatment for an additional 2 weeks. The Waon therapy group was treated daily with a far infrared-ray dry sauna at 60 °C for 15 min and then kept on bed rest with a blanket for 30 min for 2 weeks. Chest radiography, echocardiography, and plasma levels of brain natriuretic peptide (BNP) were measured before and 2 weeks after treatment. Results NYHA functional class significantly decreased after 2 weeks of treatment in both groups. Chest radiography also showed a significant decrease of the cardiothoracic ratio in both groups (Waon therapy: 57.2 ± 8.0% to 55.2 ± 8.0%, p < 0.0001; control: 57.0 ± 7.7% to 56.0 ± 7.1%, p < 0.05). Echocardiography demonstrated that left ventricular diastolic dimension (LVDd), left atrial dimension (LAD), and ejection fraction (EF) significantly improved in the Waon therapy group (LVDd: 60.6 ± 7.6 to 59.1 ± 8.4 mm, p < 0.0001; LAD: 45.4 ± 9.3 mm to 44.1 ± 9.4 mm, p < 0.05; EF: 31.6 ± 10.4% to 34.6 ± 10.6%, p < 0.0001), but not in the control group (LVDd: 58.4 ± 10.3 mm to 57.9 ± 10.4 mm; LAD: 46.3 ± 9.7 mm to 46.2 ± 10.1 mm; EF: 36.6 ± 14.1% to 37.3 ± 14.0%). The plasma concentration of BNP significantly decreased with Waon therapy, but not in the control group (Waon: 542 ± 508 pg/ml to 394 ± 410 pg/ml, p < 0.001; control: 440 ± 377 pg/ml to 358 ± 382 pg/ml). Conclusion Waon therapy is safe, improves clinical symptoms and cardiac function, and decreases cardiac size in CHF patients. Waon therapy is an innovative and promising therapy for patients with CHF.]]></description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain</subject><subject>Cardiovascular</subject><subject>Case-Control Studies</subject><subject>Chronic Disease</subject><subject>Echocardiography</subject><subject>Female</subject><subject>Heart failure</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Hyperthermia, Induced - methods</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Natriuretic peptides</subject><subject>Non-pharmacological therapy</subject><subject>Prospective Studies</subject><subject>Radiography, Thoracic</subject><subject>Treatment</subject><subject>Waon therapy</subject><issn>0914-5087</issn><issn>1876-4738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV2r1DAQhoMonj2rf8ALyZ1XrZM03aQigh6OH3BA8AMvQ3Y6YVO7bU3aI_vvTdkFwQuvEpJ5H2aeYeyZgFKA2L3syq5DLCWAKUGXAM0DthFG7wqlK_OQbaARqqjB6Ct2nVIHsIPG7B6zK2EaKSsjNmx5RwP5gMH1nLwnnBMfPf_hxoHPB4puOvF8ndwcaMh_v8N84HiI4xCQH8jFmXsX-iXSK_6F0tKf845PcUxTxoV74sf8HDDnKfI0L-3pCXvkXZ_o6eXcsu_vb7_dfCzuPn_4dPP2rsAa9FxUeRivEWQtEEnJmhBEXUlBxggwDpRXToOrmtYDSrd3hlojWtwr14paVVv24szN3fxaKM32GBJS37uBxiVZXVVaKZ2ZWybPlZj7TpG8nWI4uniyAuxq23Z2tW1X2xa0zbZz6PkFv-yP1P6NXPTmgtfnAspD3geKNmH2iNSGmN3Ydgz_57_5J459yOJd_5NOlLpxiUPWZ4VN0oL9uu57XTcYgMwR1R8FFqdW</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>Miyata, Masaaki, MD, FJCC</creator><creator>Kihara, Takashi, MD</creator><creator>Kubozono, Takuro, MD</creator><creator>Ikeda, Yoshiyuki, MD</creator><creator>Shinsato, Takuro, MD</creator><creator>Izumi, Toru, MD, FJCC</creator><creator>Matsuzaki, Masunori, MD, FJCC</creator><creator>Yamaguchi, Tetsu, MD, FJCC</creator><creator>Kasanuki, Hiroshi, MD, FJCC</creator><creator>Daida, Hiroyuki, MD, FJCC</creator><creator>Nagayama, Masatoshi, MD</creator><creator>Nishigami, Kazuhiro, MD</creator><creator>Hirata, Kumiko, MD</creator><creator>Kihara, Koichi, MD</creator><creator>Tei, Chuwa, MD, FJCC</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081001</creationdate><title>Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study</title><author>Miyata, Masaaki, MD, FJCC ; Kihara, Takashi, MD ; Kubozono, Takuro, MD ; Ikeda, Yoshiyuki, MD ; Shinsato, Takuro, MD ; Izumi, Toru, MD, FJCC ; Matsuzaki, Masunori, MD, FJCC ; Yamaguchi, Tetsu, MD, FJCC ; Kasanuki, Hiroshi, MD, FJCC ; Daida, Hiroyuki, MD, FJCC ; Nagayama, Masatoshi, MD ; Nishigami, Kazuhiro, MD ; Hirata, Kumiko, MD ; Kihara, Koichi, MD ; Tei, Chuwa, MD, FJCC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-3187f7c0251cce425ec015321e88108a04f4a70a39df0c2aba8ed81dcb4ad1543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain</topic><topic>Cardiovascular</topic><topic>Case-Control Studies</topic><topic>Chronic Disease</topic><topic>Echocardiography</topic><topic>Female</topic><topic>Heart failure</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Hyperthermia, Induced - methods</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Natriuretic peptides</topic><topic>Non-pharmacological therapy</topic><topic>Prospective Studies</topic><topic>Radiography, Thoracic</topic><topic>Treatment</topic><topic>Waon therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyata, Masaaki, MD, FJCC</creatorcontrib><creatorcontrib>Kihara, Takashi, MD</creatorcontrib><creatorcontrib>Kubozono, Takuro, MD</creatorcontrib><creatorcontrib>Ikeda, Yoshiyuki, MD</creatorcontrib><creatorcontrib>Shinsato, Takuro, MD</creatorcontrib><creatorcontrib>Izumi, Toru, MD, FJCC</creatorcontrib><creatorcontrib>Matsuzaki, Masunori, MD, FJCC</creatorcontrib><creatorcontrib>Yamaguchi, Tetsu, MD, FJCC</creatorcontrib><creatorcontrib>Kasanuki, Hiroshi, MD, FJCC</creatorcontrib><creatorcontrib>Daida, Hiroyuki, MD, FJCC</creatorcontrib><creatorcontrib>Nagayama, Masatoshi, MD</creatorcontrib><creatorcontrib>Nishigami, Kazuhiro, MD</creatorcontrib><creatorcontrib>Hirata, Kumiko, MD</creatorcontrib><creatorcontrib>Kihara, Koichi, MD</creatorcontrib><creatorcontrib>Tei, Chuwa, MD, FJCC</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyata, Masaaki, MD, FJCC</au><au>Kihara, Takashi, MD</au><au>Kubozono, Takuro, MD</au><au>Ikeda, Yoshiyuki, MD</au><au>Shinsato, Takuro, MD</au><au>Izumi, Toru, MD, FJCC</au><au>Matsuzaki, Masunori, MD, FJCC</au><au>Yamaguchi, Tetsu, MD, FJCC</au><au>Kasanuki, Hiroshi, MD, FJCC</au><au>Daida, Hiroyuki, MD, FJCC</au><au>Nagayama, Masatoshi, MD</au><au>Nishigami, Kazuhiro, MD</au><au>Hirata, Kumiko, MD</au><au>Kihara, Koichi, MD</au><au>Tei, Chuwa, MD, FJCC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study</atitle><jtitle>Journal of cardiology</jtitle><addtitle>J Cardiol</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>52</volume><issue>2</issue><spage>79</spage><epage>85</epage><pages>79-85</pages><issn>0914-5087</issn><eissn>1876-4738</eissn><abstract><![CDATA[Summary Background We conducted a prospective multicenter case–control study to confirm the clinical efficacy and safety of Waon therapy on chronic heart failure (CHF). Methods Patients ( n = 188) with CHF were treated with standard therapy for at least 1 week, and then were randomized to Waon therapy ( n = 112) or a control group ( n = 76). All patients continued conventional treatment for an additional 2 weeks. The Waon therapy group was treated daily with a far infrared-ray dry sauna at 60 °C for 15 min and then kept on bed rest with a blanket for 30 min for 2 weeks. Chest radiography, echocardiography, and plasma levels of brain natriuretic peptide (BNP) were measured before and 2 weeks after treatment. Results NYHA functional class significantly decreased after 2 weeks of treatment in both groups. Chest radiography also showed a significant decrease of the cardiothoracic ratio in both groups (Waon therapy: 57.2 ± 8.0% to 55.2 ± 8.0%, p < 0.0001; control: 57.0 ± 7.7% to 56.0 ± 7.1%, p < 0.05). Echocardiography demonstrated that left ventricular diastolic dimension (LVDd), left atrial dimension (LAD), and ejection fraction (EF) significantly improved in the Waon therapy group (LVDd: 60.6 ± 7.6 to 59.1 ± 8.4 mm, p < 0.0001; LAD: 45.4 ± 9.3 mm to 44.1 ± 9.4 mm, p < 0.05; EF: 31.6 ± 10.4% to 34.6 ± 10.6%, p < 0.0001), but not in the control group (LVDd: 58.4 ± 10.3 mm to 57.9 ± 10.4 mm; LAD: 46.3 ± 9.7 mm to 46.2 ± 10.1 mm; EF: 36.6 ± 14.1% to 37.3 ± 14.0%). The plasma concentration of BNP significantly decreased with Waon therapy, but not in the control group (Waon: 542 ± 508 pg/ml to 394 ± 410 pg/ml, p < 0.001; control: 440 ± 377 pg/ml to 358 ± 382 pg/ml). Conclusion Waon therapy is safe, improves clinical symptoms and cardiac function, and decreases cardiac size in CHF patients. Waon therapy is an innovative and promising therapy for patients with CHF.]]></abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>18922381</pmid><doi>10.1016/j.jjcc.2008.07.009</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-5087 |
| ispartof | Journal of cardiology, 2008-10, Vol.52 (2), p.79-85 |
| issn | 0914-5087 1876-4738 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733744715 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Brain Cardiovascular Case-Control Studies Chronic Disease Echocardiography Female Heart failure Heart Failure - therapy Humans Hyperthermia, Induced - methods Male Middle Aged Natriuretic Peptide, Brain - blood Natriuretic peptides Non-pharmacological therapy Prospective Studies Radiography, Thoracic Treatment Waon therapy |
| title | Beneficial effects of Waon therapy on patients with chronic heart failure: Results of a prospective multicenter study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effects%20of%20Waon%20therapy%20on%20patients%20with%20chronic%20heart%20failure:%20Results%20of%20a%20prospective%20multicenter%20study&rft.jtitle=Journal%20of%20cardiology&rft.au=Miyata,%20Masaaki,%20MD,%20FJCC&rft.date=2008-10-01&rft.volume=52&rft.issue=2&rft.spage=79&rft.epage=85&rft.pages=79-85&rft.issn=0914-5087&rft.eissn=1876-4738&rft_id=info:doi/10.1016/j.jjcc.2008.07.009&rft_dat=%3Cproquest_cross%3E733744715%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733744715&rft_id=info:pmid/18922381&rft_els_id=1_s2_0_S0914508708002001&rfr_iscdi=true |